Cited by 94

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1

Bertrand, Y, Currie, J-C, Poirier, J, Demeule, M, Abulrob, A, Fatehi, D, Stanimirovic, D, Sartelet, H, Castaigne, J-P, Béliveau, R·2011·British Journal of Cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2011.427

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. Abulrob A, Brunette E, Slinn J, Baumann E, Stanimirovic D (2008) Dynamic analysis of the blood-brain barrier disruption in experimental stroke using time domain in vivo fluorescence imaging. Mol Imaging 7 (6): 248–262 · DOI
  2. Acarregui MJ, England KM, Richman JT, Littig JL (2003) Characterization of CD34+ cells isolated from human fetal lung. Am J Physiol Lung Cell Mol Physiol 284 (2): L395–L401 · DOI
  3. Ali MJ, Navalitloha Y, Vavra MW, Kang EW, Itskovich AC, Molnar P, Levy RM, Groothuis DR (2006) Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters. Neuro Oncol 8 (2): 109–118 · DOI
  4. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26 (6): 449–462 · DOI
  5. Bertrand Y, Currie JC, Demeule M, Regina A, Che C, Abulrob A, Fatehi D, Sartelet H, Gabathuler R, Castaigne JP, Stanimirovic D, Beliveau R (2010) Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med 14 (12): 2827–2839 · DOI
  6. Bilodeau N, Fiset A, Boulanger MC, Bhardwaj S, Winstall E, Lavoie JN, Faure RL (2010) Proteomic analysis of Src family kinases signaling complexes in Golgi/endosomal fractions using a site-selective anti-phosphotyrosine antibody: identification of LRP1-insulin receptor complexes. J Proteome Res 9 (2): 708–717 · DOI
  7. Carpenter CL, Cantley LC (2005) Signal transduction systems. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 7th edn. Lippincott, Williams, and Wilkins: Philadelphia, PA, pp 73–83
  8. Castellano J, Aledo R, Sendra J, Costales P, Juan-Babot O, Badimon L, Llorente-Cortes V (2011) Hypoxia stimulates low-density lipoprotein receptor-related protein-1 expression through hypoxia-inducible factor-(alpha) in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 31 (6): 1411–1420 · DOI
  9. Che C, Yang G, Thiot C, Lacoste MC, Currie JC, Demeule M, Regina A, Beliveau R, Castaigne JP (2010) New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem 53 (7): 2814–2824 · DOI · Paper page
  10. de Vries TJ, Verheijen JH, de Bart AC, Weidle UH, Ruiter DJ, van Muijen GN (1996) Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res 56 (6): 1432–1439
  11. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, Gabathuler R, Castaigne JP, Beliveau R (2008a) Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 106 (4): 1534–1544 · DOI · Paper page
  12. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Beliveau R (2008b) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324 (3): 1064–1072 · DOI
  13. Desrosiers RR, Rivard ME, Grundy PE, Annabi B (2006) Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors. Pediatr Blood Cancer 46 (1): 40–49 · DOI
  14. Drappatz J, Brenner AJ, Rosenfeld S, Groves MD, Mikkelsen T, Schiff D, Sarantopoulos J, Wong E, Wen PY, Castaigne J (2010) ANG1005: results of a phase I study in patients with recurrent malignant glioma. J Clin Oncol 28 (15): 15s
  15. Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2 (4): 252–257 · DOI
  16. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127 (4): 679–695 · DOI
  17. Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108 (6): 779–784 · DOI · Paper page
  18. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, Kuang Y, Ye L, Lou J, Jiang C (2009) Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30 (36): 6976–6985 · DOI
  19. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res 60 (4): 883–887
  20. Laterra J, Goldstein GW (2000) Ventricular organization of cerebrospinal fluid: blood-brain barrier, brain edema, and hydrocephalus. In: Kandel ER, Schwartz JH, Jessell TM (eds). Principles of Neural Science, 4th edn, Chapter Appendix, B McGraw-Hill, Health Professions Division: New York, pp 1288–1301
  21. Lillis AP, Mikhailenko I, Strickland DK (2005) Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost 3 (8): 1884–1893 · DOI
  22. Mekhail K, Khacho M, Gunaratnam L, Lee S (2004) Oxygen sensing by H+: implications for HIF and hypoxic cell memory. Cell Cycle 3 (8): 1027–1029 · DOI
  23. Montel V, Gaultier A, Lester RD, Campana WM, Gonias SL (2007) The low-density lipoprotein receptor-related protein regulates cancer cell survival and metastasis development. Cancer Res 67 (20): 9817–9824 · DOI
  24. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwelt EA (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25 (16): 2295–2305 · DOI
  25. Navalitloha Y, Schwartz ES, Groothuis EN, Allen CV, Levy RM, Groothuis DR (2006) Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. Neuro Oncol 8 (3): 227–233 · DOI
  26. Obermeyer K, Krueger S, Peters B, Falkenberg B, Roessner A, Rocken C (2007) The expression of low density lipoprotein receptor-related protein in colorectal carcinoma. Oncol Rep 17 (2): 361–367
  27. Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Chambers AF, Weil RJ, Steeg PS (2006) Brain metastases of breast cancer. Breast Dis 26: 139–147 · DOI
  28. Provenzale JM, Mukundan S, Dewhirst M (2005) The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 185 (3): 763–767 · DOI
  29. Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, Beliveau R, Castaigne JP (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155 (2): 185–197 · DOI
  30. Sarantopoulos J, Gabrail NY, Moulder SL, Brenner AJ, Smith CL, Bouchard D, Elian K, Lawrence B, Castaigne J, Kurzrock R (2010) ANG1005: results of a phase I study in patients with advanced solid tumors and brain metastases. J Clin Oncol 28 (15): S2556 · DOI
  31. Shen J, Zhan C, Xie C, Meng Q, Gu B, Li C, Zhang Y, Lu W (2011) Poly(ethylene glycol)-block-poly(D,L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. J Drug Target 19 (3): 197–203 · DOI
  32. Song H, Li Y, Lee J, Schwartz AL, Bu G (2009) Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 69 (3): 879–886 · DOI · Paper page
  33. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS (1990) Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 265 (29): 17401–17404 · DOI · Paper page
  34. Tange Y, Miyazaki M, Iwata J, Aiko Y, Sakamoto S, Mori K (2009) Novel antitumor effect of carboplatin delivered by intracerebral microinfusion in a rat malignant glioma model. Neurol Med Chir (Tokyo) 49 (12): 572–579 · DOI
  35. Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A (2008) Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis 25 (7): 703–716 · DOI
  36. Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, Smith QR (2009) Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 26 (11): 2486–2494 · DOI
  37. Vaupel P (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13 (Suppl 3): 21–26 · DOI
  38. Warshawsky I, Broze Jr GJ, Schwartz AL (1994) The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 91 (14): 6664–6668 · DOI
  39. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19 (54): 6297–6305 · DOI
  40. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62 (13): 3803–3811

Cited by

Sorted by citations

Metadata

Authors
Bertrand, Y., Currie, J.-C., Poirier, J., Demeule, M., Abulrob, A., Fatehi, D., Stanimirovic, D., Sartelet, H., Castaigne, J.-P., & Béliveau, R.
Venue
British Journal of Cancer
Published
2011-10-25
Volume
105
Issue
11
Pages
1697-1707
ISSN
  • 0007-0920
  • 1532-1827
Cited by
94
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review